Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

M. Casarrubios,A. Cruz-Bermudez, B. Sierra-Rodero,C. Martinez,E. Nadal,M. A. Insa Molla,J. Mosquera Martinez,C. Gonzalez Ojea,M. Domine Gomez,M. Majem Tarruella,D. Rodriguez Abreu, A. Martinez-Marti,J. De Castro Carpeno,M. Cobo Dols,G. Lopez Vivanco,R. Bernabe Caro,N. Vinolas Segarra,I. C. Barneto Aranda,B. Massuti Sureda,M. Provencio Pulla

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

RNAseq is a promising approach to monitor changes in the tumor microenvironment since it allows for multiple genes evaluation. We analyzed the differential immune expression pattern between pre- and post-treatment tissue samples of stage III NSCLC patients treated with neoadjuvant chemoimmunotherapy from the NADIM trial.

查看译文

关键词

neoadjuvant chemoimmunotherapy treatment,immune gene signatures,nsclc patients,nadim trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要